Co-targeting SRC overcomes resistance to BRAF inhibitors in colorectal cancer.
Beatriz Rubio-Cuesta, Carlos Carretero-Puche, Patricia Llamas, Jacinto Sarmentero, Beatriz Gil-Calderon, Alberto Lens-Pardo, Beatriz Antón-Pascual, Eduardo Rubio-González, María Cámara-Jurado, Javier Salamanca and 4 more
Article in British journal of cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
14 authors.
Beatriz Rubio-CuestaCentro de Oncología Experimental. Grupo de Investigación en Tumores Gastrointestinales y Neuroendocrinos. Instituto de Investigación Sanitaria Hospital 12 de Octubre (imas12), Madrid, Spain.
Carlos Carretero-PucheCentro de Oncología Experimental. Grupo de Investigación en Tumores Gastrointestinales y Neuroendocrinos. Instituto de Investigación Sanitaria Hospital 12 de Octubre (imas12), Madrid, Spain.
Patricia LlamasCentro de Oncología Experimental. Grupo de Investigación en Tumores Gastrointestinales y Neuroendocrinos. Instituto de Investigación Sanitaria Hospital 12 de Octubre (imas12), Madrid, Spain.
Jacinto SarmenteroCentro de Oncología Experimental. Grupo de Investigación en Tumores Gastrointestinales y Neuroendocrinos. Instituto de Investigación Sanitaria Hospital 12 de Octubre (imas12), Madrid, Spain.
Beatriz Gil-CalderonCentro de Oncología Experimental. Grupo de Investigación en Tumores Gastrointestinales y Neuroendocrinos. Instituto de Investigación Sanitaria Hospital 12 de Octubre (imas12), Madrid, Spain.
Alberto Lens-PardoCentro de Oncología Experimental. Grupo de Investigación en Tumores Gastrointestinales y Neuroendocrinos. Instituto de Investigación Sanitaria Hospital 12 de Octubre (imas12), Madrid, Spain.ORCID http://orcid.org/0000-0002-0394-9081
Beatriz Antón-PascualCentro de Oncología Experimental. Grupo de Investigación en Tumores Gastrointestinales y Neuroendocrinos. Instituto de Investigación Sanitaria Hospital 12 de Octubre (imas12), Madrid, Spain.
Eduardo Rubio-GonzálezDepartment of General and Digestive Surgery, Hospital Universitario Doce de Octubre, Madrid, Spain.
María Cámara-JuradoDepartment of Pathology, Hospital Universitario 12 de Octubre, Madrid, Spain.
Javier SalamancaDepartment of Pathology, Hospital Universitario 12 de Octubre, Madrid, Spain.
Daniel Rueda-FernándezHereditary Cancer Laboratory, 12 de Octubre University Hospital, i + 12 Research Institute, Madrid, Spain.ORCID http://orcid.org/0000-0002-5377-8890
Marco Donatello DelcuratoloCentro de Oncología Experimental. Grupo de Investigación en Tumores Gastrointestinales y Neuroendocrinos. Instituto de Investigación Sanitaria Hospital 12 de Octubre (imas12), Madrid, Spain.
Beatriz SoldevillaCentro de Oncología Experimental. Grupo de Investigación en Tumores Gastrointestinales y Neuroendocrinos. Instituto de Investigación Sanitaria Hospital 12 de Octubre (imas12), Madrid, Spain. bsoldevilla.imas12@h12o.es.ORCID http://orcid.org/0000-0002-1118-1316
Rocio Garcia-CarboneroCentro de Oncología Experimental. Grupo de Investigación en Tumores Gastrointestinales y Neuroendocrinos. Instituto de Investigación Sanitaria Hospital 12 de Octubre (imas12), Madrid, Spain. rgcarbonero@gmail.com.ORCID http://orcid.org/0000-0002-3342-397X
Funding
Comunidad de Madrid PEJD-2016-PRE/BMD-2666Comunidad de Madrid PEJD-2017-PRE/BMD-4981Fundación Científica Asociación Española Contra el Cáncer (Scientific Foundation, Spanish Association Against Cancer) POSTDO46SOLDMinistry of Economy and Competitiveness | Instituto de Salud Carlos III (Institute of Health Carlos III) PFIS; FI20/00131Ministry of Economy and Competitiveness | Instituto de Salud Carlos III (Institute of Health Carlos III) PI16-01827Ministry of Economy and Competitiveness | Instituto de Salud Carlos III (Institute of Health Carlos III) PI19-01583
6 · The paper itself
Abstract
backgroundBRAF
methodsWe studied SRC using BRAF-mutated and wild-type CRC cell lines with CRISPR/Cas9 knockouts and lentiviral overexpression. We tested SRC, BRAF, EGFR, and JNK targeting drugs, assessing protein expression, cell viability, proliferation, migration, apoptosis, and cell cycle. CRC cell line-derived xenograft (CDX) and patient-derived xenograft (PDX) models were established for in vivo studies.
resultsSRC regulates proliferation, clonogenicity, migration and mediates BRAFi resistance in BRAF
conclusionsThese findings identify new therapeutic targets for clinical trials, potentially improving outcomes for this high-risk CRC subgroup.
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Co-targeting SRC overcomes resistance to BRAF inhibitors in colorectal cancer. · full record | OpenQuestion